ASH 2024 – Sumitomo joins the menin party
Enzomenib might be the most promising agent so far, on a cross-trial basis.
ASH 2024 – J&J mounts its first-line menin challenge
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – menin inhibitors face off again
Kura will see more combo data, while a new contender from Sumitomo emerges.
